Results 191 to 200 of about 491,092 (298)

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, EarlyView.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source

The intersection of prescription drugs and medical devices: the evaluation and funding challenges of two categories of emerging health technologies. [PDF]

Int J Technol Assess Health Care
Rodrigues C, Fu R, Ghose T, Yurga E, Nauenberg E.   +4 more
europepmc   +1 more source

The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study

American Journal of Hematology, EarlyView.
ABSTRACT Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020.
Abhilasha Borad, Michael Andersen Jr., Danielle Guffey, Hanqing Shang, Jun Y. Jiang, Maria J. Fernandez Turizo, Jonathan Berry, Jeffrey I. Zwicker, Rushad Patell, Ang Li   +9 more
wiley   +1 more source

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

American Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos, Sotirios Manganas, Charalampos Filippatos, Konstantinos Karamouzis, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios‐Athanasios Dimopoulos   +7 more
wiley   +1 more source

Characteristics of High-Cost Beneficiaries of Prescription Drugs in Kazakhstan: A Cross-Sectional Study of Outpatient Data from 2022. [PDF]

Clinicoecon Outcomes Res
Nazarbayev A, Nurbakyt A, Omirbayeva B, Akhmetzhan A, Kosherbayeva L.   +4 more
europepmc   +1 more source

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.

JAMA Health Forum, 2023
Daval CJR, Teng TW, Russo M, Kesselheim AS.   +3 more
europepmc   +1 more source

International reference pricing for prescription drugs: a landscape analysis. [PDF]

J Manag Care Spec Pharm, 2021
Rand LZ, Kesselheim AS.
europepmc   +1 more source

Assessment of Initial Stay Time and Work‐Rest Scheduling Over Consecutive Moderate‐Intensity Workdays in Hot Environments in Young and Older Males and Females

American Journal of Industrial Medicine, EarlyView.
ABSTRACT Introduction Initial stay time (IST), the duration of continuous work before core temperature reaches 38.0°C, has been characterized in young and older adults but not across consecutive work periods or in conjunction with standard work‐rest cycles.
Glen P. Kenny, Katie E. Wagar, Roberto C. Harris‐Mostert, Kristina‐Marie T. Janetos, James J. McCormick, Kelli E. King, Leonidas G. Ioannou, Ronald J. Sigal, W. Shane Journeay, Fergus K. O'Connor   +9 more
wiley   +1 more source

Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.

JAMA, 2023
Tu SS, Nagar S, Kesselheim AS, Lu Z, Rome BN.   +4 more
europepmc   +1 more source

Hepatic Glycogen Storage Diseases in Brazil: A Multicenter Study

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (
Mariana Pena Costa, Alexandre Rodrigues Ferreira, Adriana Teixeira Rodrigues, Rodrigo Rezende Arantes, Thais Costa Nascentes Queiroz, Elisa de Carvalho, Gilda Porta, Irene Kazue Miura, Maria Tereza Galvão Guiotti, Rafaella Karen Sousa Monterlei, Adriana Maria Alves de Tommaso, Gabriel Hessel, Maria Ângela Bellomo‐Brandão, Roberta Vacari de Alcantara, Maria Julia Rodrigues Teixeira de Araujo, Daniela Góis Meneses, Regina Sawamura, Cibele Dantas Ferreira Marques, Lucas Rocha Alvarenga, Marise Helena Cardoso Tofoli, Ana Cristina Vieira de Melo, Jussara Melo de Cerqueira Maia, Leticia Helena Caldas Lopes, Eleonora Druve Tavares Fagundes   +23 more
wiley   +1 more source